According to a recent LinkedIn post from JenaValve Technology Inc, initial commercial procedures using its Trilogy System have been completed in the U.S., signaling the official domestic launch of what the post describes as the first and only FDA-approved TAVR for symptomatic, severe aortic regurgitation. The post credits teams at Cedars-Sinai Medical Center, Columbia University Medical Center, and Piedmont Heart Institute with performing these first commercial cases.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post directs readers to a press release and safety information, underscoring that the device is restricted to sale on the order of a physician and carries detailed indications and contraindications. For investors, the start of U.S. commercial use suggests JenaValve is moving from clinical development toward revenue-generating activity in a niche structural heart indication.
If adoption scales, entry into the aortic regurgitation segment could position the Trilogy System as a differentiated product within the broader TAVR market, which is currently dominated by large incumbents. The first commercial cases at high-profile cardiac centers may also support further clinical validation and reimbursement traction, factors that are likely to influence future growth potential and competitive standing.